Table 1 Clinical characteristics of patients (n = 61)
From: Low cyclosporine concentrations in children and time to acute graft versus host disease
Characteristics | No (%) or Mean ± SD | aGVHD No (%) or Mean ± SD | P | |
|---|---|---|---|---|
Absence (n = 34) | Presence (n = 27) | |||
Age (years) | 0.166 | |||
< 12 | 37 (60.7%) | 18 (52.9%) | 19 (70.4%) | |
≥ 12 | 24 (39.3%) | 16 (47.1%) | 8 (29.6%) | |
Sex | 0.980 | |||
Female | 27 (44.3%) | 15 (44.1%) | 12 (44.4%) | |
Male | 34 (55.7%) | 19 (55.9%) | 15 (55.6%) | |
Body weight (kg) | 33.8 ± 20.0 | 37.2 ± 9.5 | 29.5 ± 20.1 | 0.138 |
Diagnosis | 0.219 | |||
Acute lymphoblastic leukemia | 16 (23.2%) | 7 (20.6%) | 9 (33.3%) | |
Acute myeloid leukemia | 22 (36.1%) | 14 (41.2%) | 8 (29.6%) | |
Severe plastic anemia | 11 (18.0%) | 4 (11.8%) | 7 (25.9%) | |
Myelodysplastic syndromes | 7 (11.5%) | 6 (17.6%) | 1 (3.7%) | |
Others | 5 (8.2%) | 3 (8.8%) | 2 (7.4%) | |
Donor type | 0.331 | |||
Sibling | 22 (36.1%) | 15 (44.1%) | 7 (25.9%) | |
Mismatched unrelated | 13 (21.3%) | 6 (17.6%) | 7 (25.9%) | |
Full matched unrelated | 26 (42.6%) | 13 (38.2%) | 13 (48.1%) | |
Conditioning regimen | 0.112 | |||
Bu/Cy/ATG/Flua | 13 (21.3%) | 4 (11.8%) | 9 (33.3%) | |
Bu/Cy/ATGa | 7 (11.5%) | 6 (17.6%) | 1 (3.7%) | |
Bu/Cya | 14 (23.0%) | 9 (26.5%) | 5 (18.5%) | |
Cy/TBIa | 8 (13.1%) | 6 (17.6%) | 2 (7.4%) | |
Flu/Cy/ATG/TBI | 1 (1.6%) | 0 (0%) | 1 (3.7%) | |
Flu/Cy/ATG | 10 (16.4%) | 4 (11.8%) | 6 (22.2%) | |
Flu/Cy/TBI | 7 (11.5%) | 5 (14.7%) | 2 (7.4%) | |
Cy/ATG | 1 (1.6%) | 0 (0%) | 1 (3.7%) | |
Methotrexate | 0.041 | |||
Yes | 48 (78.7%) | 30 (88.2%) | 18 (66.7%) | |
No | 13 (21.3%) | 4 (11.8%) | 9 (33.3%) | |
Voriconazole | 0.685 | |||
Yes | 6 (9.8%) | 4 (11.8%) | 2 (7.4%) | |
No | 55 (90.2%) | 30 (88.2%) | 25 (92.6%) | |
AST/ALT | 0.735 | |||
< 200 | 51 (83.6%) | 29 (85.3%) | 22 (81.5%) | |
≥ 200 | 10 (16.4%) | 5 (14.7%) | 5 (18.5%) | |
Kidney injury (NCI CTCAE) | 0.008 | |||
Grade 0–1 | 50 (82.0%) | 32 (94.1%) | 18 (66.7%) | |
Grade 2–5 | 11 (18.0%) | 2 (5.9%) | 9 (33.3%) | |
Week reached initial target CsA concentration | 0.098 | |||
0 | 2 (3.3%) | 2 (5.9%) | 0 (0.0%) | |
1 | 16 (26.2%) | 10 (29.4%) | 6 (22.2%) | |
2 | 33 (54.1%) | 20 (58.8%) | 13 (48.1%) | |
3 | 7 (11.5%) | 1 (2.9%) | 6 (22.2%) | |
4 | 3 (4.9%) | 1 (2.9%) | 2 (7.4%) | |
Initial target concentration reached before engraftment | 0.155 | |||
Yes | 44 (72.1%) | 27 (79.4%) | 17 (63.0%) | |
No | 17 (27.9%) | 7 (20.6%) | 10 (37.0%) | |
Low CsA concentrations at lag time before aGVHD occurrence | ||||
Lag days 0–6 | < 0.001 | |||
Yes | 28 (45.9%) | 8 (23.5%) | 20 (74.1%) | |
No | 33 (54.1%) | 26 (76.5%) | 7 (25.9%) | |
Lag days 7–13 | < 0.001 | |||
Yes | 20 (37.0%) | 3 (8.8%) | 17 (85.0%) | |
No | 34 (63.0%) | 31 (91.2%) | 3 (15.0%) | |
Lag days 14–20 | 0.007 | |||
Yes | 17 (38.6%) | 9 (26.5%) | 8 (80.0%) | |
No | 27 (61.4%) | 25 (73.5%) | 2 (20.0%) | |